Haresh Jhangiani

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting

Eyal Meiri, Haresh Jhangiani, James J. Vredenburgh et al. · Current Medical Research and Opinion · 2007 · 206 citations

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

Sara A. Hurvitz, Florence Dalenc, Mario Campone et al. · Breast Cancer Research and Treatment · 2013 · 76 citations · Full text

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 44 citations

Hematological Malignancy, Oncology, Transplantation +8

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

Sudhir Manda, Habte Yimer, Stephen J. Noga et al. · Clinical Lymphoma Myeloma & Leukemia · 2020 · 16 citations · Full text